eyal

­

About eyal

This author has not yet filled in any details.
So far eyal has created 84 blog entries.

Scientific Writer

March 8th, 2017|

 

Full-time or Contractor
Experienced in writing study reports for drug discovery programs including in vitro and in vivo Pharmacology studies
Reporting to CSO and working closely with Project Directors
M.Sc. in Biology or higher with at least 3 years industry experience
Experience in preparation of IND packages – advantage
Proficient in English (level of mother tongue)

Stability Coordinator/Manager, CMC

February 12th, 2017|

 

Reports to: Senior VP, Pharmaceutical Development

Date: February, 2017
JOB DESCRIPTION

 

Summary/Objective

This position is responsible for the coordination, tracking, and monitoring of all stability studies and associated time points.

Essential Functions

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions.

Provide oversight and management of the stability testing programs for API and drug […]

Principal Database Programmer

January 8th, 2017|

Quark Pharmaceuticals, Inc.

Location:  Fremont, CA

Job title: Principal Database Programmer

Reports to:  Head, Clinical Data Management

 

Position Summary:

 

The Principal Database Programmer is responsible for managing the delivery and execution of all technical aspects of study build, validation, and maintenance, including core configuration, update and migration activities for ongoing clinical studies, database revisions, timely resolution of technical issues related […]

Quark Pharmaceuticals Launches EyeActNow.com to Promote NAION Study Steps-Up Recruitment for Phase II/III Research on ‘Stroke of the Eye’

October 14th, 2016|

 

FREMONT, Calif., October 14, 2016 — Quark Pharmaceuticals, Inc. today announced the launch of www.EyeActNow.com to promote public awareness and subject recruitment for a global Phase II/III clinical study evaluating QPI-1007, an investigational drug designed to stop further vision loss in patients with early diagnosis of Non-arteritic Anterior Ischemic Optic Neuropathy, or NAION.

Often referred to […]

Quark Pharmaceuticals Chief Scientist Provides an Overview of the Company’s Clinical and Nonclinical Pipelines

September 19th, 2016|

FREMONT, Calif., Sept. 19, 2016 — Today, at the RNA Therapeutics Summit in Berlin, Germany, Quark Pharmaceuticals Inc. Chief Scientific Officer Dr. Elena Feinstein will provide an overview of Quark’s clinical and non-clinical pipelines of siRNA therapeutics focused on non-liver indications to address additional urgent unmet medical needs. RNA Therapeutics Summit is an international gathering […]

Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant

July 28th, 2016|

Treatment for Non-Arteritic Ischemic Optic Neuropathy is
in Phase II/III Study

FREMONT, Calif., July 28, 2016 — Quark Pharmaceuticals, Inc. (“Quark”) today announced that the United States Patent and Trademark Office (“USPTO”) has granted a key patent covering the treatment of patients suffering from non-arteritic anterior ischemic optic neuropathy (“NAION”) with the Company’s ocular neuroprotectant QPI-1007. The […]

Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India

June 23rd, 2016|

Bengaluru, India, and Fremont, CA, June 23, 2016        

 Biocon Ltd. (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceutical company, and Quark Pharmaceuticals, Inc., a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, announced today the randomization of the first patient in India in the pivotal global Phase II/III study of […]

Quark Pharmaceuticals to Present Keynote Address at IBC’s 18th Annual TIDES Oligonucleotide and Peptide Therapeutics Conference

May 9th, 2016|

FREMONT, Calif., May 9, 2016  — Quark Pharmaceuticals, Inc. (“Quark”) today announced a keynote address on the company’s history of oligonucleotide development will be presented at the 18TH Annual TIDES Oligonucleotide and Peptide Therapeutics Conference at 11 a.m. PDT on May 10 at the Long Beach Convention Center in Long Beach, CA. Daniel Zurr, Ph.D., […]

Transplant Genomics® and Quark Pharmaceuticals Announce Discovery and Development Collaboration

April 14th, 2016|

Pleasanton, CA, and San Francisco, CA, April 14, 2016 – Transplant Genomics Inc. (“TGI”) and Quark Pharmaceuticals, Inc. (“Quark”) today announced their joint intent to pursue a discovery and development collaboration involving the use of TGI’s TruGraf™ blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with […]

Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase III Studies and One Phase II Study of RNAi-Based Therapeutics for Kidney and Eye Indications

March 14th, 2016|

Clinical Advances with Treatments for Delayed Graft Function (DGF), Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Acute Kidney Injury (AKI) Catapult Quark Into Front Line of siRNA Companies

FREMONT, Calif., March 14, 2016 /PRNewswire/ — Quark Pharmaceuticals Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, […]